These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22514962)

  • 1. Hereditary breast and ovarian cancer.
    Barks P; Goldgar C
    JAAPA; 2012 Mar; 25(3):63-5. PubMed ID: 22514962
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
    Singer CF; Muhr D; Rappaport C; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Berger A; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):72-5. PubMed ID: 23772696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.
    Stuckey AR; Onstad MA
    Am J Obstet Gynecol; 2015 Aug; 213(2):161-5. PubMed ID: 25747548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement.
    Am Fam Physician; 2020 Feb; 101(4):233-238. PubMed ID: 32053325
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
    Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and management of hereditary breast cancer.
    Narod SA; Offit K
    J Clin Oncol; 2005 Mar; 23(8):1656-63. PubMed ID: 15755973
    [No Abstract]   [Full Text] [Related]  

  • 7. Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?
    Snyder CL; Casey MJ; Lynch HT
    Womens Health (Lond); 2015 Jul; 11(4):423-7. PubMed ID: 26246179
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of ovarian cancer risk in women with
    Walker M; Jacobson M; Sobel M
    CMAJ; 2019 Aug; 191(32):E886-E893. PubMed ID: 31405835
    [No Abstract]   [Full Text] [Related]  

  • 9. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers.
    Koskenvuo L; Svarvar C; Suominen S; Aittomäki K; Jahkola T
    Scand J Surg; 2014 Mar; 103(1):34-40. PubMed ID: 24177987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetical aspects of surgical treatment in patients with hereditary breast cancer].
    Bit-Sava EM
    Vestn Khir Im I I Grek; 2014; 173(5):27-30. PubMed ID: 25823331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
    Meaney-Delman D; Bellcross CA
    Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thank you for sharing.
    Nature; 2015 Apr; 520(7549):585. PubMed ID: 25925435
    [No Abstract]   [Full Text] [Related]  

  • 15. The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.
    Afghahi A; Kurian AW
    Curr Treat Options Oncol; 2017 May; 18(5):27. PubMed ID: 28439798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond BRCA1 and BRCA2.
    King-Spohn K; Pilarski R
    Curr Probl Cancer; 2014; 38(6):235-48. PubMed ID: 25497410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
    Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.
    Yang S; Axilbund JE; O'Leary E; Michalski ST; Evans R; Lincoln SE; Esplin ED; Nussbaum RL
    Ann Surg Oncol; 2018 Oct; 25(10):2925-2931. PubMed ID: 29998407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel.
    Kwong A; Shin VY; Au CH; Law FB; Ho DN; Ip BK; Wong AT; Lau SS; To RM; Choy G; Ford JM; Ma ES; Chan TL
    J Mol Diagn; 2016 Jul; 18(4):580-94. PubMed ID: 27157322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.